Vertex Pharmaceuticals

VRTX

Market cap $126B

The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 9.7% yield and -10% NAV discount. Selections emphasize sector diversification, long-term outperformance, sustainable distributions, and attractive valuations, with a focus on both equity and credit-oriented CEFs. CEFs are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone.

CVS Health is making changes that could improve its business this year. Vertex Pharmaceuticals should see strong commercial and clinical progress in 2026.

Centessa Pharmaceuticals has a promising candidate, but plenty of work remains before it can launch it. Vertex Pharmaceuticals has a rich lineup of approved medicines and a deep pipeline of exciting candidates.

This company is the global leader in its specialty area and has successfully expanded into other areas, too. This player aims to generate $13 billion in sales this year.

Vertex Pharmaceuticals' market-beating returns over the past 10 years wouldn't have been enough to turn $100,000 into $1 million. Though it still has strong prospects, this goal seems far too difficult to achieve.

I believe Vertex Pharmaceuticals Incorporated's bull run has come to an end. There's a divergence between its stock price growth over the past 5 months and the performance of Journavx and the cystic fibrosis franchise. So, in Q4, Trikafta+Kaftrio sales declined 3.1% quarter-on-quarter to about $2.57 billion, missing my "base case" scenario by $45 million.

Vertex Pharmaceuticals is the leader in cystic fibrosis treatment. The company has also expanded into other areas in recent years, winning approval for two new drugs.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in TD Cowen's 46th Annual Health Care Conference. Reshma Kewalramani, President and Chief Executive Officer will participate in a fireside chat on Tuesday, March 3, 2026, at 9:10 a.m. ET. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com, in the "Investors" section under the "News and Events" page. A replay of the conference webcast.

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Vertex Q4 earnings miss estimates, but revenues top forecasts on strong CF sales and momentum from new launches like Alyftrek, Casgevy and Journavx.